About 30 results found for searched term "JAK2 Inhibitor V" (0.109 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M3735 | JAK2 Inhibitor V | JAK |
| NSC 42834, Z3 | ||
| JAK2 Inhibitor V, Z3 is a novel specific inhibitor of Jak2 which inhibits Jak2-V617F and Jak2-WT autophosphorylation in a dose-dependent manner but was not cytotoxic to cells at concentrations that inhibited kinase activity. | ||
| M1700 | Momelotinib (CYT387) | JAK |
| LM-1149; Momelotinib; CYT 11387 | ||
| Momelotinib (CYT387) is a small-molecule, ATP-competitive JAK1/JAK2 inhibitor with IC50 of 11 and 18 nM respectively. | ||
| M1787 | INCB18424 | JAK |
| Ruxolitinib | ||
| Ruxolitinib (INCB018424) is a first-in-class, potent, selective JAK1/2 inhibitor with an IC50 of 3.3 nM/2.8 nM. It is more than 130-fold more selective for JAK1, JAK2, and JAK3 than JAK3. It can be used in studies related to pemphigus, myelofibrosis and vitiligo. | ||
| M1804 | NVP-BSK805 dihydrochloride | JAK |
| NVP-BSK805, BSK805 2HCl | ||
| NVP-BSK805 dihydrochloride is a potent and selective quinoxaline JAK2 inhibitor with IC50 values of 0.48, 0.56 and 0.58 nM for JAK2 JH1, FL JAK V617F and FL JAK2 wt respectively. | ||
| M2039 | Baricitinib | JAK |
| INCB28050, LY3009104 | ||
| Baricitinib (INCB28050) is an oral JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, respectively. | ||
| M2566 | XL019 | JAK |
| XL019 is a potent and selective JAK2 inhibitor with IC50 of 2.2 nM, exhibiting >50-fold selectivity over JAK1, JAK3 and TYK2. | ||
| M3030 | S-Ruxolitinib | JAK |
| S-Ruxolitinib; INCB18424 | ||
| S-Ruxolitinib is the chirality of INCB018424, which is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. | ||
| M3535 | Gandotinib | JAK |
| LY2784544 | ||
| Gandotinib (LY2784544) is a potent JAK2 inhibitor with IC50 of 3 nM, effective in JAK2V617F, 8- and 20-fold selective versus JAK1 and JAK3. | ||
| M5315 | Baricitinib phosphate | JAK |
| INCB028050; LY3009104 | ||
| Baricitinib phosphate(INCB 028050; LY 3009104) is a selective JAK1 and JAK2 inhibitor with IC50 of 5.9 nM and 5.7 nM, ~70 and ~10-fold selective versus JAK3 and Tyk2, no inhibition to c-Met and Chk2. | ||
| M5944 | Ruxolitinib phosphate | JAK |
| INCB018424 phosphate; INCB 018424 phosphate; INCB-018424 phosphate; Ruxolitinib | ||
| Ruxolitinib phosphate(INCB018424 phosphate) is the first potent, selective, JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM, >130-fold selectivity for JAK1/2 versus JAK3. | ||
| M8220 | NSC 33994 | Others |
| NSC 33994 is a potent and specific Jak2 inhibitor that inhibits a notorious mutation, Jak2-V617F, found in large number of myeloproliferative neoplasms. | ||
| M11186 | NVP-BSK805 | JAK |
| BSK805 | ||
| NVP-BSK805 is a potent, selective, ATP competitive JAK2 inhibitor with an IC50 of 0.5 nM, which is more than 20 times more selective than acting on JAK1, JAK3 and TYK2. | ||
| M13852 | Momelotinib sulfate | JAK |
| CYT387 sulfate salt | ||
| Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor of JAK1/JAK2 with IC50 of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC50=155 nM). In addition, Momelotinib is an inhibitor of activin A receptor type I (ACVR1). It may be used in studies related to myelofibrosis. | ||
| M27897 | SD-1029 | JAK |
| SD-1029 is a JAK2/STAT3 inhibitor. SD-1029 inhibits STAT3 nuclear translocation. SD-1029 is an inhibitor of STAT3 activation due to inhibition of JAK2 phosphorylation. | ||
| M28015 | Ilginatinib hydrochloride | JAK |
| NS-018 hydrochloride | ||
| Ilginatinib hydrochloride (NS-018 hydrochloride) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). | ||
| M28016 | Ilginatinib | JAK |
| NS-018 | ||
| Ilginatinib (NS-018) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). | ||
| M28195 | JAK-IN-1 | JAK |
| JAK-IN-1 is a JAK1/2/3 inhibitor with IC50s of 0.26, 0.8 and 3.2 nM, respectively. JAK-IN-1 shows improved selectivity for JAK3 over JAK1. | ||
| M28231 | Ilginatinib maleate | JAK |
| NS-018 maleate | ||
| Ilginatinib maleate (NS-018 maleate) is a highly active and orally bioavailable JAK2 inhibitor, with an IC50 of 0.72 nM, 46-, 54-, and 31-fold selectivity for JAK2 over JAK1 (IC50, 33 nM), JAK3 (IC50, 39 nM), and Tyk2 (IC50, 22 nM). | ||
| M28279 | Fedratinib hydrochloride hydrate | JAK |
| TG-101348 hydrochloride hydrate; SAR 302503 hydrochloride hydrate | ||
| Fedratinib hydrochloride hydrate (TG-101348 hydrochloride hydrate) is a potent, selective, ATP-competitive and orally active JAK2 inhibitor with IC50s of 3 nM for both JAK2 and JAK2V617F kinase. Fedratinib hydrochloride hydrate shows 35- and 334-fold selectivity over JAK1 and JAK3, respectively. | ||
| M28334 | JAK-IN-3 | JAK |
| JAK-IN-3 (compound 22) is a potent JAK inhibitor, with IC50 values of 3 nM, 5 nM, 34 nM and 70 nM for JAK3, JAK1, TYK2 and JAK2, respectively. | ||
| M31205 | G5-7 | JAK |
| G5-7 is an orally active and allosteric JAK2 inhibitor, selectively inhibits JAK2 mediated phosphorylation and activation of EGFR (Tyr1068) and STAT3 by binding to JAK2. G5-7 induces cell cycle arrest, apoptosis and possesses antiangiogenic effect. G5-7 has the potential for glioma study. | ||
| M40835 | OST-122 | JAK |
| OST-122 is a JAK3/SYK2/ARK5 multi-target inhibitor for ulcerative colitis related studies. | ||
| M41702 | JAK-IN-27 | JAK |
| JAK-IN-27 is an orally active and potent JAKS family kinase inhibitor with IC50s of 3.0 nM (TYK2), 7.7 nM (JAK1), 629.6 nM (JAK3), respectively. | ||
| M41705 | JAK-IN-25 | JAK |
| JAK-IN-25 is a potent JAK inhibitor with IC50s of 6 nM, 21 nM, 8 nM, 1051 nM for TYK2, JAK1, JAK2, JAK3, respectively. | ||
| M49504 | JAK-2/3-IN-3 | Apoptosis |
| JAK-2-/3-IN-3 is a potent JAK2/3 inhibitor with IC50s of 13.00 and 14.86 nM for JAK2 and JAK3, respectively. | ||
| M49571 | JAK1/TYK2-IN-1 | JAK |
| JAK1/TYK2-IN-1 is a dual inhibitor of TYK2 and JAK1 (IC50 = 29 and 41 nM respectively). | ||
| M49572 | JAK1/TYK2-IN-3 | JAK |
| JAK1/TYK2-IN-3 is a potent, selective and orally active dual TYK2/JAK1 inhibitor with IC50 values of 6 and 37 nM, respectively. | ||
| M49573 | JAK1/TYK2-IN-4 | JAK |
| JAK1/TYK2-IN-4 is a dual inhibitor of JAK and TYK2, with IC50s of 39 nM and 21 nM, respectively. | ||
| M49580 | JAK-2/3-IN-2 | JAK |
| JAK-2/3-IN-2 is a JAK2 and JAK3 inhibitor with IC50s of 23.85 nM and 18.9 nM, respectively. | ||
| M49581 | JAK2/FLT3-IN-1 | JAK |
| JAK2/FLT3-IN-1 is a potent and orally active dual JAK2/FLT3 inhibitor with IC50 values of 0.7 nM, 4 nM, 26 nM and 39 nM for JAK2, FLT3, JAK1 and JAK3, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
